Ipca Laboratories Ltd.
IPCALABHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
10 transcript(s)/analyst meet(s) served; 1 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (2 of 10 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20210601 | 2021-03-31 | yes | |
| TRANSCRIPT | 20210809 | 2021-06-30 | yes | |
| TRANSCRIPT | 20211118 | 2021-09-30 | yes | |
| TRANSCRIPT | 20220217 | 2021-12-31 | yes | |
| TRANSCRIPT | 20220527 | 2022-03-31 | yes | |
| TRANSCRIPT | 20220812 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221116 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230220 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230814 | 2023-06-30 | yes | |
| TRANSCRIPT | 20240819 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241118 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250602 | 2025-03-31 | yes | |
| DUPLICATE | 20250602 | 2025-03-31 | no | |
| TRANSCRIPT | 20250814 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251117 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260218 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260604 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260817 | 2026-06-30 | yes |
IPCALAB
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
The closes are adjusted for every split and bonus on record inside the period this series covers, and each adjustment is checked against the price move on its ex-date.
| Last close | 1,997.10 |
| 52-week range | 1268.7 – 2009.6 |
| Return 1M | 3.56% |
| Return 3M | 23.41% |
| Return 1Y | 48.11% |
| Return 3Y | 123.84% |
| Return 5Y | 66.36% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 2,788.00 |
| Other income | 25.00 |
| Total income | 2,813.00 |
| Cost of materials consumed | 638.00 |
| Purchases of stock-in-trade | 141.00 |
| Changes in inventories | 19.00 |
| Employee benefit expense | 602.00 |
| Finance costs | 12.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.45 | 0.00 |
| institutions foreign | 0.11 | 0.00 |
| institutions domestic | 0.37 | -0.00 |
| mutual funds | 0.31 | -0.00 |
| public | 0.55 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| DUPLICATE | 2025-03-31 | 1 |
| TRANSCRIPT | 2026-06-30 | 17 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 1,601.00 | 1,546.00 | 1,512.00 | 1,588.00 | 2,034.00 | 2,053.00 | 2,033.00 | 2,093.00 | 2,355.00 | 2,245.00 | 2,247.00 | 2,309.00 | 2,556.00 | 2,392.00 | 2,388.00 | 2,788.00 |
| Other income | 36.00 | 31.00 | 36.00 | 45.00 | 39.00 | 22.00 | 19.00 | 21.00 | 26.00 | 20.00 | 26.00 | 33.00 | 28.00 | 20.00 | 94.00 | 25.00 |
| Total income | 1,637.00 | 1,577.00 | 1,548.00 | 1,632.00 | 2,073.00 | 2,075.00 | 2,052.00 | 2,113.00 | 2,381.00 | 2,265.00 | 2,273.00 | 2,342.00 | 2,584.00 | 2,413.00 | 2,482.00 | 2,813.00 |
| Cost of materials consumed | 479.00 | 362.00 | 413.00 | 432.00 | 609.00 | 610.00 | 565.00 | 545.00 | 589.00 | 482.00 | 660.00 | 617.00 | 570.00 | 564.00 | 593.00 | 638.00 |
| Purchases of stock-in-trade | 139.00 | 147.00 | 99.00 | 121.00 | 144.00 | 116.00 | 109.00 | 119.00 | 154.00 | 188.00 | 87.00 | 127.00 | 127.00 | 130.00 | 149.00 | 141.00 |
| Changes in inventories | -43.00 | 53.00 | 80.00 | -38.00 | -75.00 | -29.00 | 12.00 | -21.00 | 16.00 | -3.00 | -39.00 | -52.00 | 85.00 | -36.00 | -50.00 | 19.00 |
| Employee benefit expense | 319.00 | 318.00 | 327.00 | 358.00 | 426.00 | 459.00 | 466.00 | 488.00 | 510.00 | 485.00 | 501.00 | 543.00 | 538.00 | 546.00 | 533.00 | 602.00 |
| Finance costs | 9.00 | 11.00 | 18.00 | 31.00 | 44.00 | 33.00 | 29.00 | 24.00 | 23.00 | 17.00 | 22.00 | 19.00 | 20.00 | 18.00 | 20.00 | 12.00 |
| Depreciation and amortisation | 64.00 | 67.00 | 70.00 | 69.00 | 90.00 | 100.00 | 98.00 | 99.00 | 100.00 | 98.00 | 100.00 | 100.00 | 103.00 | 108.00 | 107.00 | 111.00 |
| Other expenses | 446.00 | 450.00 | 412.00 | 407.00 | 609.00 | 566.00 | 559.00 | 569.00 | 645.00 | 629.00 | 609.00 | 658.00 | 692.00 | 655.00 | 680.00 | 720.00 |
| Total expenses | 1,413.00 | 1,408.00 | 1,419.00 | 1,381.00 | 1,847.00 | 1,854.00 | 1,839.00 | 1,823.00 | 2,036.00 | 1,898.00 | 1,939.00 | 2,011.00 | 2,135.00 | 1,984.00 | 2,032.00 | 2,241.00 |
| Profit before exceptional items and tax | 224.00 | 169.00 | 129.00 | 252.00 | 225.00 | 221.00 | 213.00 | 290.00 | 345.00 | 368.00 | 333.00 | 331.00 | 450.00 | 428.00 | 450.00 | 572.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 68.00 | -137.00 | 0.00 | 0.00 | 0.00 | -205.00 | 0.00 | -58.00 | 18.00 | -46.00 | 0.00 |
| Profit before tax | 224.00 | 169.00 | 129.00 | 252.00 | 225.00 | 289.00 | 77.00 | 290.00 | 345.00 | 368.00 | 128.00 | 331.00 | 392.00 | 446.00 | 404.00 | 572.00 |
| Current tax | 76.00 | 54.00 | 38.00 | 83.00 | 89.00 | 67.00 | 72.00 | 84.00 | 98.00 | 101.00 | 89.00 | 96.00 | 108.00 | 112.00 | 102.00 | 133.00 |
| Deferred tax | 1.00 | -0.00 | 10.00 | 2.00 | -1.00 | -0.00 | 2.00 | 7.00 | 1.00 | -10.00 | -27.00 | 0.00 | -0.00 | -30.00 | -7.00 | 16.00 |
| Tax expense | 77.00 | 54.00 | 48.00 | 86.00 | 88.00 | 66.00 | 74.00 | 91.00 | 99.00 | 91.00 | 62.00 | 96.00 | 108.00 | 82.00 | 95.00 | 149.00 |
| Profit for the period | 146.00 | 110.00 | 78.00 | 164.00 | 136.00 | 221.00 | 1.00 | 199.00 | 246.00 | 276.00 | 64.00 | 233.00 | 281.00 | 364.00 | 307.00 | 424.00 |
| Profit attributable to owners | -3.00 | 6.00 | 77.00 | 163.00 | 145.00 | 180.00 | 60.00 | 192.00 | 229.00 | 248.00 | 68.00 | 233.00 | 283.00 | 326.00 | 299.00 | 402.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | 2.00 | 1.00 | -9.00 | 41.00 | -58.00 | 7.00 | 16.00 | 28.00 | -4.00 | -0.00 | -2.00 | 37.00 | 8.00 | 22.00 |
| Other comprehensive income | -3.00 | 6.00 | 2.00 | -1.00 | -1.00 | 1.00 | -8.00 | 0.00 | -5.00 | -13.00 | -7.00 | 5.00 | 11.00 | -1.00 | 27.00 | -20.00 |
| Total comprehensive income | 143.00 | 116.00 | 80.00 | 163.00 | 136.00 | 222.00 | -7.00 | 200.00 | 241.00 | 264.00 | 57.00 | 238.00 | 292.00 | 363.00 | 334.00 | 404.00 |
| Earnings per share, basic | 5.67 | 4.25 | 3.02 | 6.42 | 5.72 | 7.09 | 2.35 | 7.58 | 9.05 | 9.78 | 2.67 | 9.19 | 11.14 | 12.86 | 11.79 | 15.84 |
| Earnings per share, diluted | 5.67 | 4.25 | 3.02 | 6.42 | 5.72 | 7.09 | 2.35 | 7.58 | 9.05 | 9.78 | 2.67 | 9.19 | 11.14 | 12.86 | 11.79 | 15.84 |
Annual results, as filed
| Line | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|---|
| Revenue from operations | 4,649.00 | 5,420.00 | 5,830.00 | 6,244.00 | 7,705.00 | 8,940.00 | 9,646.00 |
| Other income | 67.00 | 63.00 | 67.00 | 126.00 | 125.00 | 93.00 | 174.00 |
| Total income | 4,716.00 | 5,483.00 | 5,896.00 | 6,370.00 | 7,830.00 | 9,032.00 | 9,821.00 |
| Cost of materials consumed | 1,460.00 | 1,597.00 | 1,664.00 | 1,709.00 | 2,216.00 | 2,277.00 | 2,344.00 |
| Purchases of stock-in-trade | 360.00 | 326.00 | 480.00 | 497.00 | 490.00 | 548.00 | 533.00 |
| Changes in inventories | -176.00 | -195.00 | -130.00 | 101.00 | -131.00 | -46.00 | -54.00 |
| Employee benefit expense | 921.00 | 1,014.00 | 1,177.00 | 1,288.00 | 1,708.00 | 1,984.00 | 2,160.00 |
| Finance costs | 16.00 | 9.00 | 8.00 | 46.00 | 138.00 | 85.00 | 76.00 |
| Depreciation and amortisation | 210.00 | 209.00 | 232.00 | 262.00 | 357.00 | 398.00 | 418.00 |
| Other expenses | 1,177.00 | 1,134.00 | 1,328.00 | 1,723.00 | 2,100.00 | 2,451.00 | 2,685.00 |
| Total expenses | 3,969.00 | 4,094.00 | 4,761.00 | 5,625.00 | 6,879.00 | 7,696.00 | 8,162.00 |
| Profit before exceptional items and tax | 747.00 | 1,389.00 | 1,136.00 | 745.00 | 950.00 | 1,336.00 | 1,659.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | -108.00 | -205.00 | -86.00 |
| Profit before tax | 747.00 | 1,389.00 | 1,136.00 | 745.00 | 843.00 | 1,131.00 | 1,573.00 |
| Current tax | 141.00 | 249.00 | 207.00 | 230.00 | 310.00 | 372.00 | 418.00 |
| Deferred tax | -6.00 | -8.00 | 17.00 | 23.00 | 3.00 | -28.00 | -37.00 |
| Tax expense | 135.00 | 240.00 | 224.00 | 253.00 | 313.00 | 344.00 | 381.00 |
| Profit for the period | 604.00 | 1,141.00 | 890.00 | 479.00 | 523.00 | 785.00 | 1,184.00 |
| Profit attributable to owners | 606.00 | 1,140.00 | 884.00 | 471.00 | 547.00 | 738.00 | 1,141.00 |
| Profit attributable to non-controlling interests | -3.00 | 1.00 | 6.00 | 8.00 | -24.00 | 48.00 | 43.00 |
| Other comprehensive income | 4.00 | -0.00 | 3.00 | 7.00 | -9.00 | -25.00 | 43.00 |
| Total comprehensive income | 607.00 | 1,141.00 | 893.00 | 486.00 | 513.00 | 761.00 | 1,227.00 |
| Earnings per share, basic | 47.77 | 90.11 | 34.85 | 18.58 | 21.57 | 29.08 | 44.98 |
| Earnings per share, diluted | 47.73 | 90.11 | 34.85 | 18.58 | 21.57 | 29.08 | 44.98 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 7,898.00 | 8,626.00 | 11,384.00 | 11,101.00 | 11,424.00 | 11,761.00 | 12,263.00 | 12,370.00 |
| Non-current assets | 3,344.00 | 3,437.00 | 5,664.00 | 5,562.00 | 5,743.00 | 5,492.00 | 5,747.00 | 5,993.00 |
| Current assets | 4,545.00 | 5,189.00 | 5,716.00 | 5,536.00 | 5,674.00 | 5,967.00 | 6,252.00 | 6,374.00 |
| Property, plant and equipment | 2,328.00 | 2,572.00 | 4,342.00 | 4,340.00 | 4,291.00 | 4,069.00 | 4,168.00 | 4,441.00 |
| Capital work-in-progress | 246.00 | 122.00 | 267.00 | 324.00 | 485.00 | 616.00 | 777.00 | 762.00 |
| Goodwill | 54.00 | 38.00 | 91.00 | 91.00 | 91.00 | 91.00 | 83.00 | 83.00 |
| Other intangible assets | 154.00 | 141.00 | 135.00 | 123.00 | 130.00 | 107.00 | 113.00 | 103.00 |
| Inventories | 1,823.00 | 1,743.00 | 2,452.00 | 2,471.00 | 2,518.00 | 2,560.00 | 2,516.00 | 2,731.00 |
| Trade receivables | 1,103.00 | 989.00 | 1,760.00 | 1,687.00 | 1,814.00 | 1,874.00 | 2,077.00 | 2,014.00 |
| Cash and cash equivalents | 387.00 | 1,258.00 | 434.00 | 209.00 | 256.00 | 167.00 | 213.00 | 437.00 |
| Total equity and liabilities | 7,898.00 | 8,626.00 | 11,384.00 | 11,101.00 | 11,424.00 | 11,761.00 | 12,263.00 | 12,370.00 |
| Equity | 5,859.00 | 5,915.00 | 7,561.00 | 7,727.00 | 8,118.00 | 8,388.00 | 8,866.00 | 9,524.00 |
| Equity share capital | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 |
| Other equity | 5,753.00 | 5,817.00 | 6,123.00 | 6,307.00 | 6,675.00 | 6,923.00 | 7,402.00 | 8,038.00 |
| Total liabilities | 2,039.00 | 2,711.00 | 3,823.00 | 3,374.00 | 3,306.00 | 3,372.00 | 3,397.00 | 2,846.00 |
| Non-current liabilities | 654.00 | 905.00 | 1,137.00 | 1,019.00 | 910.00 | 986.00 | 859.00 | 539.00 |
| Current liabilities | 1,385.00 | 1,806.00 | 2,686.00 | 2,356.00 | 2,396.00 | 2,384.00 | 2,537.00 | 2,307.00 |
| Borrowings, non-current | 433.00 | 652.00 | 703.00 | 580.00 | 457.00 | 543.00 | 400.00 | 109.00 |
| Borrowings, current | 288.00 | 806.00 | 1,250.00 | 807.00 | 699.00 | 758.00 | 805.00 | 595.00 |
| Trade payables | 576.00 | 525.00 | 795.00 | 776.00 | 906.00 | 846.00 | 822.00 | 940.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 372.00 | 806.00 | 243.00 | 945.00 | 740.00 | 1,321.00 | 780.00 | 1,142.00 |
| Net cash from investing activities | -773.00 | -725.00 | -1,165.00 | -1,292.00 | -301.00 | -870.00 | -298.00 | -247.00 |
| Net cash from financing activities | -100.00 | 507.00 | 131.00 | -553.00 | -336.00 | -283.00 | -211.00 | -754.00 |
| Purchase of property, plant and equipment | 290.00 | 494.00 | 212.00 | 411.00 | 345.00 | 776.00 | 461.00 | 652.00 |
| Net increase in cash | -500.00 | 588.00 | -791.00 | -900.00 | 102.00 | 169.00 | 271.00 | 142.00 |
| con:CFO.BEFORE_TAX | 460.00 | 1,029.00 | 369.00 | 1,241.00 | 899.00 | 1,683.00 | 976.00 | 1,556.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 88.00 | 224.00 | 126.00 | 296.00 | 160.00 | 361.00 | 196.00 | 414.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 65.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 16.00 | 36.00 | 1.00 | 9.00 | 3.00 | 5.00 | 1.00 | -4.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 11.00 | 1,543.00 | 1,543.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 45.00 | 25.00 | 25.00 | 27.00 | 27.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 46.29 | 46.29 | 46.29 | 46.29 | 46.30 | 46.30 | 46.30 | 44.72 | 44.72 | 44.72 | 0.45 | 0.45 | 0.45 | 0.45 |
| Domestic institutions | 34.06 | 35.19 | 35.05 | 34.52 | 34.37 | 33.78 | 34.23 | 35.68 | 36.06 | 36.20 | 0.37 | 0.37 | 0.37 | 0.37 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 29.61 | 0.30 | 0.31 | 0.31 | 0.31 |
| Insurance companies | 3.61 | 4.26 | 4.12 | 4.54 | 4.67 | 4.63 | 4.87 | 5.19 | 5.64 | 5.83 | 0.06 | 0.06 | 0.05 | 0.05 |
| Foreign institutions | 10.58 | 10.05 | 9.86 | 10.27 | 10.51 | 10.85 | 10.83 | 11.07 | 10.76 | 10.67 | 0.10 | 0.11 | 0.11 | 0.11 |
| Public | 53.71 | 53.71 | 53.71 | 53.71 | 53.70 | 53.70 | 53.70 | 55.28 | 55.28 | 55.28 | 0.55 | 0.55 | 0.55 | 0.55 |
| Non-institutional | 9.07 | 8.48 | 8.81 | 8.92 | 8.82 | 9.06 | 8.64 | 8.53 | 8.46 | 8.41 | 0.08 | 0.07 | 0.07 | 0.07 |
| Shares outstanding | 253704218 | 253704218 | 253704218 | 253704218 | 253704218 | 253704218 | 253704218 | 253704218 | 253704218 | 253704218 | 253704218 | 253704218 | 253704218 | 253704218 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| IPCA PHARMACEUTICALS, INC. USA | Subsidiaries | Investment, Purchase of goods or services, Sale of g | 994,300,000.00 | 3 |
| IPCA LABORATORIES UK LTD | Subsidiaries | Sale of goods or services | 599,700,000.00 | 1 |
| LYKA LABS LTD | Joint Ventures | Any other transaction, Interest received, Investment | 469,100,000.00 | 5 |
| KREBS BIOCHEMICALS & INDUSTRIES LTD. | Associates | Advance, Any other transaction, Interest received, L | 397,400,000.00 | 10 |
| AVIK PHARMACEUTICAL LTD | Joint Ventures | Any other transaction, Interest received, Loan, Purc | 258,000,000.00 | 5 |
| MAKERS LABORATORIES LTD. | Other Related Party | Advance, Any other transaction, Purchase of fixed as | 242,900,000.00 | 5 |
| UNICHEM LABORATORIES LTD. | Subsidiaries | Any other transaction, Purchase of fixed assets, Pur | 221,800,000.00 | 6 |
| MR. PREMCHAND GODHA | Key Management Personnel | Remuneration | 65,400,000.00 | 1 |
| MR. AJIT KUMAR JAIN | Key Management Personnel | Remuneration | 42,500,000.00 | 1 |
| MR.PRANAY GODHA | Key Management Personnel | Remuneration | 41,300,000.00 | 1 |
| IPCA FOUNDATION | Other Related Party | Any other transaction | 34,000,000.00 | 1 |
| MR. PRASHANT GODHA | Key Management Personnel | Remuneration | 32,300,000.00 | 1 |
| IPCA PHARMA NIGERIA LTD. | Subsidiaries | Sale of goods or services | 15,000,000.00 | 1 |
| NIPRA INDUSTRIES PVT. LTD. | Other Related Party | Purchase of goods or services | 12,800,000.00 | 1 |
| TROPHIC WELLNESS PVT. LTD. | Subsidiaries | Any other transaction, Sale of goods or services | 9,900,000.00 | 3 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2025-06-02 | Q4FY25 | ATORIES LIMITED, LABORA, May 30, 2025, TOR – IPCA, a Laboratories Limited | Read the call |
| 2023-08-14 | Q1FY24 | LABORATORIES LIMITED | Read the call |
| 2023-02-20 | Q3FY23 | A Laboratories Limited, ATORIES LIMITED, COMPAN, February 16, 2023, LABORA, SEL AND | Read the call |
| 2022-11-16 | Q2FY23 | Read the call | |
| 2022-08-12 | Q1FY23 | Read the call | |
| 2022-05-27 | Q4FY22 | ECTOR, IPCA, LABO, MR. N, May 25, 2022, ORATORIES LIMITED, ORIES LIMITED, atoriesLimited Q | Read the call |
| 2022-02-17 | Q3FY22 | February 15, 2022, LIMIT, MR. H, OUNSEL AND, arnings | Read the call |
| 2021-11-18 | Q2FY22 | LABORATORIES LIMITED | Read the call |
| 2021-08-09 | Q1FY22 | LABORATORIES LIMITED | Read the call |
| 2021-06-01 | Q4FY21 | Read the call |
What they said about it, quarter by quarter
| Topic | Q1FY24 | Q2FY22 | Q2FY23 | Q3FY22 | Q3FY23 | Q4FY21 | Q4FY22 | Q4FY25 |
|---|---|---|---|---|---|---|---|---|
| Capex | And any details on our CAPEX plans and any update in the existing work for the plants that is going on? | Sir can you please provide some update on capacity addition at Dewas and Ratlam on UPS side? | — | So, I would say that March 22, and March 23, probably in two years the whole credit may be utilized, whatever remaining credits are there that may, be… | So right now wing board stage, not finalize any kind of capex on that front rig one question. | Sir, is it possible for you to give a little bit more colour in terms of how do you see the export opportunity, I think six months back also we were t… | — | My second question is if you can update on some of th was working on, so some new plants, et cetera, where work has o. |
| Capital allocation | Sir, the second thing is about the Unichem acquisition, so what is the way forward, sir, in fact the first part of the trade, we see this that has hap… | — | — | Sir, I have actually two questions about the recent acquisition that wemade in Lyka Labs. | — | — | Sir, just one question on the US business, our acquisition of our stake in Lyka, can you sort of expand on the rationale and what is the progress? | Sir, integrated, ou acquisition its by -- so -- w witnessing. |
| Costs | — | The first question again on the input cost given we are highly backward integrated should not that be kind of blunting the impact of the material cost… | Transcript – IPCA Laboratories Q2 FY23 Earnings Call - 4 - Management Team I would say that, almost around, on material to material wise, somewhere th… | And this you expect to come down by Q1 or you were just mentioning about the input cost? | And then there was a high freight cost and t d the testing increases, all of that has impacted very badly and . k from here on, with the cost pressure… | — | And my last question before I get back in the queue, given we continue to be high pressure on the input cost part, whether it is raw materials part or… | — |
| Debt and cash | — | — | — | So, what kind of management controldo we have or will we have over this company and do we intend to help them reduce the finance cost and raising work… | — | — | — | — |
| Demand | 44 crores due to poor demand of our antimalarial APIs. | Normally what happens that we have almost around three to four months order in pipeline always so those order prices cannot be revised and when your p… | These are the two geographies where the major impact we have seen is, basically because of slowdown in the demand and customers postponing the order e… | As far as generics are concerned, pricing is a regular phenomenon depending on the how the prices of API’s are behaving, and negotiations with the buy… | And overall for pharma market in ame 1.61%, '20, it o on a continuous lso improving our mbers. have improves its over last calendar roxychloroquine is… | Last financial year, we had Hydroxychloroquine formulation business sales of almost around 37 Crores for the quarter in domestic market in view of sig… | The normal business has also grown, but because of COVID there was exceptional demand in the market for Antibacterials, Antimalarials and also Cough a… | So whatever f crores with o another 5 to 6 is a pipeline f now developm |
| Guidance | Overall business guidelines for FY24, domestic business, we expect that industry will grow around 10% and our growth may remain around 12% to 14% for … | Sir firstly on the overall guidance for FY2022 given the first half FY2022 performance, would you like to revise the full year guidance? | So, two things here Sir, could you give us some sense of what is the outlook for your API business here on for the export market? | Probably some business will get even impacted in Q4 FY22 but we expect that business should get normalized from the first quarter of next financial ye… | We expect almost around 15% reduction in the control se ng in the –whatever, we have almost around 104 SKUs on which d. | Overall, if you look at our business guidance for the current financial year, we feel that because we did a substantial amount of additional business … | Few more products are under currently here, trials are going on and we expect significant improvement in that also, but some of the stages where there… | There is an improvement of almost around -- an increase e have delivered better margins as against the guidelines given fo guidance for the year was a… |
| Margin | This is mainly due to margin improvements on formulation business with lower input cost and overall improvement in productivity of the field force. | Overall as far as the EBITDA numbers are concerned right now we are not in position to give the guidelines because the input cost rises are significan… | So, but Sir can, again if I look at the mix, mix must improve right, on last couple of quarters basis and the prices have come up, so, why is gross ma… | On margin front on standalone accounts if we look at in Q3 we have delivered a gross margin of almost around 67.5% as against first nine months gross … | It’s just impurities or since have pa This quarter, in third quarte cost rise was issues and hig And KSM pr holding, becau margin in tim short-term is… | We have improved our overall gross margin during the quarter, Q4 to 72% as against 68% Q4 last financial year. | The Q4 EBITDA got impacted due to impairment in the value of investment of almost around Rs. | Consolidated There is agai INR305 crore EBITDA mar of around 2. |
| People | And if you can update about the Dewas site commissioning and execution and utilization, sir? | That number has not increased that is what I said so accept whatever inflation related and increments to people other than that there is no change in … | The new, second unit, and what is the utilization of the first unit and obviously you have already indicated that Dewas first unit will be contributin… | So, I believe that for FY22 we’ll be using roughly 180 crore out of that and then for FY23 would be 180 crores utilization roughly 15% of our PBT in e… | — | Sir, can you provide our capacity utilization at various plants in terms of API and formulation? | Sir, first of all, can you give us an update on the ongoing projects, whether it is the Dewas or the debottlenecking activities in Ratlam, Aurangabad … | Only silver lining, they have a lot of capacity availa there is no need for any fresh investment in facility creation So what could be the utilization… |
| Pricing | So, it has more to do with the pricing aspect and very limited to do with the volume aspect? | Common product like paracetamol which used to be a year about Rs.350 now we are buying almost around Rs.900 the pricing now and every pill you sell yo… | Nikhil Mathur So, my point is that the steady present growth, it would have a component of obviously volume and pricing increase as well. | And on the India business you suggested that in September, October time we will take a lot of price increases. | And also because of this reduction in pricing and all. | Sir, can you comment on our API portfolio pricing scenario how it will pan out? | So, order flow itself is very low from institutions around that time because Artemisinin prices has gone up significantly higher and therefore there w… | Are there an how do you look at your API, volume and the price. and pricing was at peak during COVID time. |
| Revenue growth | Domestic formulation business has delivered a growth of almost around 14% for the Q1 FY24. The impact of NLEM product price reduction in Q4 FY23 of ar… | Let us say in the Q2 as against around 10% growth in the topline our material costs gone up by almost around 17% and that trend will continue maybe ev… | So, it has very recently started the first page, we started some intermediate business from unit 1, for our captive consumption, that did not contribu… | The second reason was the exceptional business of Hydroxychloroquine, Chloroquinewhat we had in last financial year that has impacted this business.Ov… | So overall, material co d I think overall margins will improve. st is higher because the numbers have moved up in current y % kind of overall increase… | We feel that our domestic formulation business will be very strong in the current financial year and overall we IPCA Laboratories Limited May 31, 2021… | 551 crores for Q4 FY22. Export formulation business recorded a growth of around 3% from Rs. | In last quarter of r market share by around 9 basis points to almost around 2.0 24. e and chronic segment, we had delivered better growth compa A, ove… |
What they said they would do
Sentences in which management set an expectation. Each names the speaker and the page of the transcript it came from.
| Date | Quarter | Who | What they said |
|---|---|---|---|
| 2022-02-17 | Q3FY22 | MR. H | Sir, just want to clarify, did you give a guidance of 20% growth in revenue in quarter four? |
| 2022-02-17 | Q3FY22 | MR. H | So, we have been growing around 15% year-on-year on this therapy and current year also, we expect that kind of growth excluding the exceptional business in last financial year, but on HydroxychloroquineChloroquine shipments to the various all these promotional market. |
| 2022-02-17 | Q3FY22 | MR. H | So, current year also the business growth in these markets around 15% and for all of the year we expect that kind of growth to be there, but excluding that kind of exceptional business what we had on Chloroquine and Hydroxychloroquine in last financial year. |
| 2022-02-17 | Q3FY22 | MR. H | And just lastly, if I may ask on a institutional anti-malaria, so considering the nine month sales of almost about 240 crores and then we are guiding for 350. |
| 2022-05-27 | Q4FY22 | MR. N | First quarter growth may be little lower because first quarter, in April and May, because of your delta variance spread and all and broad base treatments and all those significant higher offtake of Antibacterials and Cough and Cold, so on that base, the growth may be little slower, but for whole of the year we should be able to do a business growth of almost around 13%. |
| 2023-02-20 | Q3FY23 | A Laboratories Limited | We expect almost around 15% reduction in the control se ng in the –whatever, we have almost around 104 SKUs on which d. |
| 2023-02-20 | Q3FY23 | A Laboratories Limited | For the first nine months, th und 11%, and I think for whole of the year we should be gro to 18%, the fourth quarter growth will be further significant in ent. |
| 2023-02-20 | Q3FY23 | A Laboratories Limited | It’s a 3.88%, marginally improve our gross st around INR 16 inancial year. higher promotional dditions of almost productive in next ge, and we expect neric formulations gin for the fourth pricing and price e are confident that to ask questions. e. at 1,200. |
| 2023-02-20 | Q3FY23 | A Laboratories Limited | We expect it to grow mu wer. has declined by around 37%. |
| 2023-02-20 | Q3FY23 | A Laboratories Limited | We expect one more product approval that cou d INR 50 crores, INR 60 crores addition in the business. |
| 2023-02-20 | Q3FY23 | A Laboratories Limited | So tax rate is likely to be in the range of around 29% to 30% k oratories Limited ebruary 16, 2023 year. |
| 2023-02-20 | Q3FY23 | A Laboratories Limited | And we expect that current year, they should 14 million to GBP 15 million kind of business with around 27 rgins in current year. oratories Limited ebruary 16, 2023 schedule. |